Comparative Effectiveness of Tocilizumab as Monotherapy Versus TNF inhibitors in Combination with Conventional Synthetic Disease Modifying Antirheu-matic Drugs in Bio-naive Patients with Rheumatoid Arthritis

被引：0
|
作者：
Lauper, K. [1 ,2 ]
Kvien, T. K. [3 ]
Codreanu, C. [4 ]
Hernandez, M., V [5 ]
Iannone, I. [6 ]
Kristianslund, E. K. [3 ]
Lukina, G. [7 ]
Nordstrom, D. C. [8 ,9 ]
Pavelka, K. [10 ]
Rotar, Z. [11 ]
Santos, M. J. [12 ,13 ]
Gale, S. L. [14 ]
John, M. [15 ]
Luder, Y. [15 ]
Courvoisier, D. S. [1 ]
Gabay, C. [1 ,2 ]
机构：
[1] Geneva Univ Hosp, Geneva, Switzerland
[2] SCQM Registry, Zurich, Switzerland
[3] Diakonhjemmet Hosp, Dept Rheumatol, Oslo, Norway
[4] Univ Med & Pharm, Ctr Rheumat Dis, Bucharest, Romania
[5] Hosp Clin Barcelona, Rheumatol Dept, Barcelona, Spain
[6] Univ Hosp Bari, GISEA, Bari, Italy
[7] Inst Rheumatol, ARBITER, Moscow, Russia
[8] ROB FIN Helsinki Univ Hosp, Helsinki, Finland
[9] Univ Helsinki, Helsinki, Finland
[10] Charles Univ Prague, Prague, Czech Republic
[11] Univ Med Ctr Ljubljana, BioRx Si, Ljubljana, Slovenia
[12] Hosp Garcia de Orta, Rheumatol Dept, Almada, Portugal
[13] Reuma Pt, Lisbon, Portugal
[14] Genentech Inc, San Francisco, CA USA
[15] F Hoffmann La Roche, Basel, Switzerland
来源：
SWISS MEDICAL WEEKLY | 2018年 / 148卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SSRP 35
引用
收藏
页码：20S / 20S
页数：1
相关论文
共 50 条
  • [41] Comparative Cost-Effectiveness of Tofacitinib With Continuing Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs for Active Rheumatoid Arthritis in South Korea
    Ha, So-Young
    Shim, Yoon-Bo
    Lee, Min-Young
    Koo, Bon-San
    Kim, Jae-Hoon
    Jeon, Ja-Young
    Yoo, Hyun-Jeong
    Kim, Young-Joo
    Shin, Ju-Young
    Park, Mi-Hai
    RHEUMATOLOGY AND THERAPY, 2021, 8 (01) : 395 - 409
  • [42] Comparative effectiveness of abatacept versus TNF inhibitors in rheumatoid arthritis patients who are ACPA and shared epitope positive
    Leslie R. Harrold
    Keith Wittstock
    Sheila Kelly
    Xue Han
    Joe Zhuo
    Amy Schrader
    Nicole Middaugh
    Page C. Moore
    Vadim Khaychuk
    Advances in Rheumatology, 64
  • [43] Comparative Cost-Effectiveness of Tofacitinib With Continuing Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs for Active Rheumatoid Arthritis in South Korea
    So-Young Ha
    Yoon-Bo Shim
    Min-Young Lee
    Bon-San Koo
    Jae-Hoon Kim
    Ja-Young Jeon
    Hyun-Jeong Yoo
    Young-Joo Kim
    Ju-Young Shin
    Mi-Hai Park
    Rheumatology and Therapy, 2021, 8 : 395 - 409
  • [44] Subcutaneous Tocilizumab in Monotherapy or in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Latin American Patients With Moderate to Severe Active Rheumatoid Arthritis A Multicenter, Phase IIIb Study
    Mysler, Eduardo
    Cardiel, Mario H.
    Xavier, Ricardo M.
    Lopez, Alejandra
    Ramos-Esquivel, Allan
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2020, 26 : S180 - S186
  • [45] Cost-effectiveness of TNF inhibitors vs synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a Markov model study based on two longitudinal observational studies
    Kvamme, Maria K.
    Lie, Elisabeth
    Uhlig, Till
    Moger, Tron A.
    Kvien, Tore K.
    Kristiansen, Ivar S.
    RHEUMATOLOGY, 2015, 54 (07) : 1226 - 1235
  • [46] Comparative effectiveness of abatacept versus TNF inhibitors in rheumatoid arthritis patients who are ACPA and shared epitope positive
    Harrold, Leslie R.
    Wittstock, Keith
    Kelly, Sheila
    Han, Xue
    Zhuo, Joe
    Schrader, Amy
    Middaugh, Nicole
    Moore, Page C.
    Khaychuk, Vadim
    ADVANCES IN RHEUMATOLOGY, 2024, 64 (01)
  • [47] Sustained Long-Term Retention Rates of Abatacept in Combination with Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Elderly Patients with Rheumatoid Arthritis
    Sato, Shuzo
    Matsumoto, Haruki
    Temmoku, Jumpei
    Fujita, Yuya
    Matsuoka, Naoki
    Yashiro-Furuya, Makiko
    Asano, Tomoyuki
    Suzuki, Eiji
    Watanabe, Hiroshi
    Kanno, Takashi
    Migita, Kiyoshi
    MEDICINA-LITHUANIA, 2021, 57 (09):
  • [48] Etanercept in combination with conventional disease-modifying antirheumatic drugs (DMARDs) in the treatment of rheumatoid arthritis patients intolerant to methotrexate
    Koyama, Yoshinobu
    Shiraishi, Hirokazu
    Ohta, Toshiyuki
    Uchino, Ayumi
    MODERN RHEUMATOLOGY, 2012, 22 (01) : 100 - 108
  • [49] Comparative Efficacy Of Novel Disease-Modifying Antirheumatic Drugs As Monotherapy and In Combination With Methotrexate In Rheumatoid Arthritis Patients With An Inadequate Response To Traditional Disease-Modifying Antirheumatic Drugs: A Network Meta-Analysis.
    Buckley, Felicity
    Finckh, Axel
    Huizinga, Thomas W. J.
    Dejonckheere, Fred
    Jansen, Jeroen P.
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S201 - S202
  • [50] Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a Register study
    Joensuu, Jaana T.
    Aaltonen, Kalle J.
    Aronen, Pasi
    Sokka, Tuulikki
    Puolakka, Kari
    Tuompo, Riitta
    Korpela, Markku
    Vasala, Mikko
    Ilva, Kirsti
    Nordstrom, Dan
    Blom, Marja
    RHEUMATOLOGY, 2016, 55 (10) : 1803 - 1811
12345